RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arbutus Biopharma Stock

Arbutus Biopharma ROA 2024

Arbutus Biopharma ROA

-0.5

Ticker

ABUS

ISIN

CA03879J1003

WKN

A14XMD

In 2024, Arbutus Biopharma's return on assets (ROA) was -0.5, a 41.92% increase from the -0.36 ROA in the previous year.

Arbutus Biopharma Aktienanalyse

What does Arbutus Biopharma do?

Arbutus Biopharma Corp is a biopharmaceutical company that focuses on developing novel treatment methods for viral diseases. The company, based in Vancouver, Canada, was founded in 2008. The history of Arbutus Biopharma Corp began with the merger of Tekmira Pharmaceuticals and OnCore Biopharma in 2015. The merger strengthened the company and expanded its ability to develop innovative therapies for Hepatitis B and Hepatitis D viruses. The ability to bring the companies together also demonstrates the team, consisting of experienced experts from various areas such as the healthcare industry, biotech engineering, finance, and pharmacy. The business model of Arbutus Biopharma Corp is to explore, develop, and market novel treatment methods for viral diseases. Marketing is done through partnerships with other companies that commercialize the products. The company relies on research and development agreements to enter into synergistic partnerships that work on the same wavelength. One of the key divisions of Arbutus Biopharma Corp is the development of RNA interference (RNAi) therapies. These therapies aim to suppress the genetic information that leads to viral replication in cells. The company has an extensive patent portfolio and comprehensive expertise in the field of RNAi therapy. RNAi therapy opens up a new paradigm in the treatment of viral diseases. The company has also developed products such as the HBV Antisense platform. The HBV Antisense platform utilizes a special type of RNA-based medication to suppress the production of proteins necessary for the replication of the Hepatitis B virus. This strategy allows for the reduction of viral RNA replication and strengthens the immune system to fight against or prevent viral infections. The company also pursues an advanced pipeline in the preclinical phase to develop a melanocortin receptor antagonist and an artificial antibody against Hepatitis B. Another business area of Arbutus Biopharma Corp is collaboration with other companies to outsource innovative technologies and products. One of the key partnerships is with Roivant Sciences Ltd. Roivant Sciences Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative therapy approaches. The partnership between Arbutus Biopharma Corp and Roivant Sciences Ltd creates a win-win situation for both, bringing about synergies and enabling capital and risk sharing. In summary, Arbutus Biopharma Corp is a biopharmaceutical company that focuses on the development of novel therapies for viral diseases. The company has a broad portfolio of innovative products in the field of RNAi therapy and HBV Antisense platform. Arbutus Biopharma Corp strives to achieve advancements in the development of therapies for viral diseases through partnerships and alliances with other companies. Arbutus Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Arbutus Biopharma's Return on Assets (ROA)

Arbutus Biopharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Arbutus Biopharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Arbutus Biopharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Arbutus Biopharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Arbutus Biopharma stock

What is the Return on Assets (ROA) of Arbutus Biopharma this year?

The Return on Assets (ROA) of Arbutus Biopharma is -0.5 undefined this year.

What was the ROA of Arbutus Biopharma compared to the previous year?

The ROA of Arbutus Biopharma has increased by 41.92% compared to the previous year.

What consequences do high ROA have for investors of Arbutus Biopharma?

A high ROA is advantageous for investors of Arbutus Biopharma, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Arbutus Biopharma?

A low ROA can be unfavorable for investors of Arbutus Biopharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Arbutus Biopharma affect the company?

An increase in ROA of Arbutus Biopharma can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Arbutus Biopharma impact the company?

A reduction in the ROA of Arbutus Biopharma can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Arbutus Biopharma?

Some factors that can influence the ROA of Arbutus Biopharma include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Arbutus Biopharma important for investors?

The ROA of Arbutus Biopharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Arbutus Biopharma take to improve ROA?

To improve ROA, Arbutus Biopharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Arbutus Biopharma pay?

Over the past 12 months, Arbutus Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arbutus Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Arbutus Biopharma?

The current dividend yield of Arbutus Biopharma is .

When does Arbutus Biopharma pay dividends?

Arbutus Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arbutus Biopharma?

Arbutus Biopharma paid dividends every year for the past 0 years.

What is the dividend of Arbutus Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arbutus Biopharma located?

Arbutus Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arbutus Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arbutus Biopharma from 7/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/11/2024.

When did Arbutus Biopharma pay the last dividend?

The last dividend was paid out on 7/11/2024.

What was the dividend of Arbutus Biopharma in the year 2023?

In the year 2023, Arbutus Biopharma distributed 0 USD as dividends.

In which currency does Arbutus Biopharma pay out the dividend?

The dividends of Arbutus Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Arbutus Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Arbutus Biopharma

Our stock analysis for Arbutus Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arbutus Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.